Non-small cell lung cancer care increasingly pairs a targeted agent with chemotherapy chosen from genomic evidence. The 98-gene lung panel splits its content into sixty-three targeted-therapy genes and thirty-six chemotherapy-response genes. This division lets one report speak to both halves of a combined treatment plan. Payers increasingly expect combined rationale documented in a single genomic report.
Tissue or plasma enters extraction, then a single capture library covers all ninety-eight selected loci. Sequencing output is parsed by two annotation tracks so targeted and chemo genes stay clearly separated. Pharmacogenomic entries flag variants tied to platinum or pemetrexed tolerance and dosing. A combined summary maps each finding to a role in the concurrent regimen. Tumor fraction estimation gates the run so low-input plasma still yields usable calls.
Patients starting first-line combination therapy use the panel to confirm both driver and chemo-fit status. Those with borderline performance may be tested to avoid regimens their genetics predict will underperform. Progressive cases are re-profiled to decide whether the targeted or chemo arm should change.
Findings return in roughly eight working days with a dual-section layout for the two gene groups. The report marks which alterations support adding versus withholding a specific chemotherapy class. Clinicians receive a plain-language addendum linking results to combination rationale. Portal upload of pathology notes helps annotators prioritize the reported variants.
Extracted libraries are kept under controlled storage for the stated re-test window. Cross-border specimen transport uses logged cold chain to protect nucleic material. Bulk oncology network orders get portal batching and consolidated dispatch. Forecast-based scheduling prevents the stockouts that disrupt recurring combination regimens.
Q: How does the panel split targeted and chemotherapy genes? A: It reports sixty-three targeted-therapy genes and thirty-six chemotherapy-response genes in separate sections of one result.
Q: Can results support a combined targeted plus chemo plan? A: Yes, the dual layout shows driver status and chemo tolerance together so the clinician can build a concurrent regimen.
Q: Is the report formatted for multidisciplinary review? A: A plain-language addendum and clear section split make the document suitable for tumor board discussion.
Q: What specimen types are accepted for the 98-gene test? A: Formalin-fixed tissue or plasma cell-free DNA is accepted, with the lab confirming sufficiency before sequencing.
Non-small cell lung cancer care increasingly pairs a targeted agent with chemotherapy chosen from genomic evidence. The 98-gene lung panel splits its content into sixty-three targeted-therapy genes and thirty-six chemotherapy-response genes. This division lets one report speak to both halves of a combined treatment plan. Payers increasingly expect combined rationale documented in a single genomic report.
Tissue or plasma enters extraction, then a single capture library covers all ninety-eight selected loci. Sequencing output is parsed by two annotation tracks so targeted and chemo genes stay clearly separated. Pharmacogenomic entries flag variants tied to platinum or pemetrexed tolerance and dosing. A combined summary maps each finding to a role in the concurrent regimen. Tumor fraction estimation gates the run so low-input plasma still yields usable calls.
Patients starting first-line combination therapy use the panel to confirm both driver and chemo-fit status. Those with borderline performance may be tested to avoid regimens their genetics predict will underperform. Progressive cases are re-profiled to decide whether the targeted or chemo arm should change.
Findings return in roughly eight working days with a dual-section layout for the two gene groups. The report marks which alterations support adding versus withholding a specific chemotherapy class. Clinicians receive a plain-language addendum linking results to combination rationale. Portal upload of pathology notes helps annotators prioritize the reported variants.
Extracted libraries are kept under controlled storage for the stated re-test window. Cross-border specimen transport uses logged cold chain to protect nucleic material. Bulk oncology network orders get portal batching and consolidated dispatch. Forecast-based scheduling prevents the stockouts that disrupt recurring combination regimens.
Q: How does the panel split targeted and chemotherapy genes? A: It reports sixty-three targeted-therapy genes and thirty-six chemotherapy-response genes in separate sections of one result.
Q: Can results support a combined targeted plus chemo plan? A: Yes, the dual layout shows driver status and chemo tolerance together so the clinician can build a concurrent regimen.
Q: Is the report formatted for multidisciplinary review? A: A plain-language addendum and clear section split make the document suitable for tumor board discussion.
Q: What specimen types are accepted for the 98-gene test? A: Formalin-fixed tissue or plasma cell-free DNA is accepted, with the lab confirming sufficiency before sequencing.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
